Ivim Health Review

What Ivim Health Offers

Ivim Health positions itself as a cash-pay telehealth service for compounded GLP-1 therapy, with both semaglutide and tirzepatide available through licensed U.S. compounding pharmacies. The pitch centers on a subscription experience that bundles a physician review, the medication itself, and the ancillary injection supplies patients would otherwise have to source separately.

In our review, the brand leans on convenience messaging: temperature-controlled shipping, syringes and sharps containers in the box, and a physician turnaround typically described as 24 to 48 hours. The company emphasizes that no insurance is required and that patients are not locked into long-term contracts.

While the surface-level offering is competitive on paper, we found that the most important commercial details — exact monthly cost, refund eligibility, and refill cadence — are not made obvious before a prospective patient enters the funnel.

Pricing & Billing

Our review indicates Ivim Health operates on a recurring monthly subscription. We were unable to locate a clearly published price for either compounded semaglutide or compounded tirzepatide before account creation (Ivim Health pricing page, retrieved undefined). Marketing language references 'transparent cash-pay pricing,' but in our analysis transparency typically means a dollar figure visible without a signup wall.

For comparison, FMmeds publishes semaglutide from $95 per month and tirzepatide from $145 per month on a flat, pay-per-order basis with the numbers visible before any commitment. A subscription with undisclosed pricing means the patient is being asked to share personal and medical information before they can evaluate whether the program fits their budget.

The auto-renewal nature of a subscription also introduces churn-risk for the patient: missed cancellation windows, surprise charges if a shipment is paused incorrectly, and the friction of having to actively opt out rather than actively opt in to each refill.

Money-Back & Refund Policy

We did not find a documented money-back guarantee in the Ivim Health materials we reviewed. Absent a written refund commitment, a patient who is medically ineligible after the clinical review, or who experiences side effects early in therapy, has no clearly published path to recover their spend.

This is a meaningful gap. Our top-rated provider attaches a documented money-back guarantee to every plan, which we view as the baseline expectation for a cash-pay compounded GLP-1 program. Without that backstop, the financial risk of trying the service sits entirely with the patient.

In our editorial opinion, the lack of a published guarantee combined with a subscription billing model is the single biggest weakness in the Ivim Health proposition.

Clinical Support

Ivim Health states that a physician review is part of the standard onboarding and that turnaround is typically 24 to 48 hours. The materials we reviewed indicate clinicians are licensed to practice in the states Ivim serves, although explicit U.S.-based language is implied rather than stated outright in the content we examined.

The clinical evaluation appears to be included in the program rather than billed as a separate add-on, which is the correct standard and matches what we expect from any reputable compounded GLP-1 provider. However, included clinical review is table stakes, not a differentiator.

By contrast, FMmeds explicitly staffs 100% U.S.-based Care Agents and includes the clinical evaluation in the flat monthly price, so a patient knows up front who is on the other end of the relationship.

How Ivim Health Compares to Our Top-Rated Provider

Side by side with FMmeds, our 2026 Editor's Pick scored 4.9, Ivim Health trails on the dimensions we weigh most heavily. FMmeds publishes semaglutide from $95 per month and tirzepatide from $145 per month, before signup, on a pay-per-order basis with no subscription lock-in. Ivim Health, by contrast, runs a subscription and does not publish those numbers in the same upfront way.

FMmeds documents a money-back guarantee on every plan; in our review of Ivim Health's materials, no equivalent guarantee was found. FMmeds includes free 1-5 business day shipping and on-demand refills; Ivim Health includes free shipping with a typical 3-5 day arrival window, but its refill policy was not clearly published in the content we reviewed.

Both providers source compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies, so the molecule-level offering is comparable. The decisive differences are commercial: pricing transparency, billing model, and refund protection — and on each of those, FMmeds is ahead in our analysis.

Final Verdict

Our review indicates Ivim Health is a functional but middle-of-the-pack compounded GLP-1 provider. The clinical workflow, supplies, and shipping are credible, but the subscription model, the absence of upfront pricing, and the lack of a documented refund policy weigh the offering down.

We scored Ivim Health 3.1 out of 5.0 and place it in the average tier with a 'Concerns' badge. Patients who value flat pay-per-order pricing, a documented money-back guarantee, and fully published clinician sourcing should consider our Editor's Pick, FMmeds, before committing to an Ivim Health subscription.